Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is a reasonable target for SCKT. I think it is possible that your targets could even be exceeded in 2017. However, that is a long way out and lots can happen between now and then. What I really wonder is exactly what their new products are and how they expand their market.
Thanks.
PSIX is getting some love on the heals of the analyst and investors meeting this week. I was in attendance and liked what I heard.
OML.V/OLNCF Nice results from Omni-Lite
http://finance.yahoo.com/news/omni-lite-industries-reports-strong-133000017.html
PFHO is getting some love.
Agreed
FDVF was up 43% today!
The PFHO CEO purchased 1500 shares in the open market. 1K was at $10.72 and the other 500 was at $8.00.
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=11014115-1097-9150&type=sect&TabIndex=2&companyid=169229&ppu=%252fdefault.aspx%253fcik%253d1138476
The PFHO CEO purchased 1500 shares in the open market. 1K was at $10.72 and the other 500 was at $8.00.
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=11014115-1097-9150&type=sect&TabIndex=2&companyid=169229&ppu=%252fdefault.aspx%253fcik%253d1138476
TIK is in with a great quarter. They reported Non-GAAP EBITDA of $0.30/share.
http://finance.yahoo.com/news/tel-instrument-electronics-corp-reports-123000611.html
Daily
I find them by combing through filings.
I expect SCKT GM to remain near 50%. Q4'15 and Q1'16 will be slightly lower than Q3'15 because of the large SOMO order that will hit in those two quarters. SOMO orders have somewhat lower margin. After that, margins should be more stable.
They have very good operating leverage because their sales are mainly done by distributors. The main work they do to obtain sales is to support developers in integrating their software. So, there isn't that much of an increase in operating expenses to increase sales for existing products.
On the share count question, I don't have that information handy. I'd have to look through the share information in their filings to give you a good answer.
FDVF is in with another great quarter. They reported $0.013/share. That is great for a stock that last traded at $0.18.
http://www.otcmarkets.com/financialReportViewer?symbol=FDVF&id=146975
FDVF is in with another great quarter. They reported $0.013/share. That is great for a stock that last traded at $0.18.
http://www.otcmarkets.com/financialReportViewer?symbol=FDVF&id=146975
SCKT
Revenue for SCKT has grown in each of the past two fiscal years. I didn't go back any further than that. The history is as follows:
2014 $17.021M
2013 $15.661M
2012 $13.565M
YTD revenue has been flat but they are expecting a big Q4 so 2015 revenue should show another year of growth.
Revenue for the barcode scanners has been growing nicely. The overall revenue has been impacted by the drop in revenue from their legacy SOMO Windows Mobile handheld computer. That device is going end of life in 2016 so the bleeding from there is about to end.
The new products will start adding to revenue a bit in 2016. I'm not sure how much they will add in 2016 but I would imagine their contribution will be significant in 2017. They haven't even announced exactly what these products are yet so it is difficult to gauge at this point.
I hope that helps.
It is very unlikely that they replace that in a quarter. However, their costs associated with that revenue are largely outsourced. So, IMO they should be able to scale their costs to the size of their revenue.
Sell 100 shares of WLDN for the SwingTrade Portfolio for $8.79. They disappointed in their report yesterday.
I just added to PFHO.
RX.V/BIOYF is in with another good quarter. They reported EPS of $0.08/share.
IMO this company has many years of growth ahead of it.
http://finance.yahoo.com/news/biosyent-releases-results-third-quarter-130000267.html
The author you are talking about is Chris Mayer. He wrote the book 100-Baggers.
I was recently interviewed.
Episode 11 - The Life of a Full-Time MicroCap Investor with Mike Schellinger, MicroCapClub.com
http://planetmicrocap.podbean.com/e/episode-11-the-life-of-a-full-time-microcap-investor-with-mike-schellinger-microcapclubcom/
SBOTF to uplist - http://www.otcmarkets.com/stock/SBOTF/news?id=118127
I picked up some $16.60s.
SCKT reported a nice bottom line of diluted EPS of $0.09 on revenue of $4.5M. Based upon the conference call, I'm estimating that revenue for Q4 increases to $4.8M. They are working on some new products in RFID and NFC that will be coming out soon. The conference call is highly recommended.
http://finance.yahoo.com/news/socket-mobile-reports-profitable-third-200100413.html
EACO reported great annual and Q4 results. They reported EPS of $0.75 for the year vs. a stock price of only $5.20.
The Q4 bottom line was improved (ignoring one time items in 2014) with earnings of $0.21/share.
The book value of the stock is $5.36/share with cash and securities of $1.47/share.
The outlook sounds good as they are planning to grow headcount in fiscal 2016.
The big question is whether Ceiley will sell some and at what price.
The report can be found here: http://finance.yahoo.com/news/eaco-corporation-reports-record-annual-200100187.html
Sell 2000 shares of OLNCF / OML.V for the SwingTrade Portfolio at $1.4484. 2000 shares remain.
Omni-Lite reports second best nine months on record
http://finance.yahoo.com/news/omni-lite-reports-second-best-123000450.html
That was a nice TIK quarter!
Yeah. That comment of mine was off the mark. The earnings in the quarter was really three things. It was higher catalyst sales, benchtop sales, and GM. Catalyst sales were a result of filling the backlog that was there. Catalyst sales have always been very lumpy but were the largest reason for the top line increase. The benchtop sales were what I mentioned. The third factor was GM. GM has been low in some of the recent quarters especially in the June and September 2014 quarters. It looks like that is now rectified. I haven't had a chance to investigate why GM was lower in those prior quarters.
PFHO has a new 5% owner. The Everakes own 40,101 shares.
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10938851-1116-12078&type=sect&TabIndex=2&companyid=169229&ppu=%2fdefault.aspx%3fcik%3d1138476
PFHO has a new 5% owner. The Everakes own 40,101 shares.
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10938851-1116-12078&type=sect&TabIndex=2&companyid=169229&ppu=%2fdefault.aspx%3fcik%3d1138476
SCND is somewhat interesting. Here is what I have so far.
The Catalyst Research backlog is impressive at $2,570,400. However, 90% of that backlog is for one large Chinese order and likely isn't sustainable. The backlog figures out to $642,600 on average per quarter for each of the next four quarters. Obviously, it will not be recognized equally in each quarter.
In fiscal 2015 they had $2,315,900 in revenue for the Catalyst Research division. Backlog going into fiscal 2015 was $453,000. Given the above, I'm going to estimate Catalyst Research revenue in fiscal 2016 of $4.4M.
The Benchtop sales are a bit hard to figure. In the fiscal Q3'15 10-Q they indicated that they had an unusual backlog of $300K in this segment. They further added color stating: " Although typically there is no significant backlog of orders for the Benchtop Laboratory Equipment Operations, due to production delays and increased number of orders during the period, the Company had a backlog of such products of approximately $300,000 as of March 31, 2015, all of which has been fulfilled as of the date of this report." This is the reason for the higher earnings in Q4 and also I'm sure one reason why they didn't break out Q4 results. Benchtop sales have been a bit higher in each of the last two quarters. They seem unusually high so I'm going to stick with repeating $5.4M as they did in 2015. One important thing to note is that 2015 Benchtop Revenue was higher because of an acquisition.
Given the above, I'm going to go with the following model for fiscal 2016:
Benchtop Revenue = $5.4M
Catalyst Research Revenue = $4.4M
Bio-processing Systems Revenue = $0.15M
Total Revenue = $9.815M
GM = 40%
Op. Ex. = $3.4M
Tax rate = 24% (what they paid when they were profitable in 2013)
Share count = 1.48M
Diluted EPS = $0.27/share
GM is a pretty big variable in the above equation. It is possible that GM is as high as say 43% or maybe as low as 38% which could have a substantial impact on my estimate. Also, I'm not sure how the higher mix of Catalyst Research Revenue will impact GM.
Also, if they can keep benchtop sales at $1.5M/quarter, there is some upside there.
I have no idea on the timing of the Catalyst Backlog. It could be back end loaded or front end loaded for the year.
No Position.
Thoughts?
SCKT has been getting some love the past couple of days. It just printed $2.45 which is a level it hasn't seen since July.